EA201692049A1 - Гетероарилзамещенные гетероциклилсульфоны - Google Patents

Гетероарилзамещенные гетероциклилсульфоны

Info

Publication number
EA201692049A1
EA201692049A1 EA201692049A EA201692049A EA201692049A1 EA 201692049 A1 EA201692049 A1 EA 201692049A1 EA 201692049 A EA201692049 A EA 201692049A EA 201692049 A EA201692049 A EA 201692049A EA 201692049 A1 EA201692049 A1 EA 201692049A1
Authority
EA
Eurasian Patent Office
Prior art keywords
substituted heterocyclic
heteroaryl substituted
sulfones
heterocyclic sulfones
compounds
Prior art date
Application number
EA201692049A
Other languages
English (en)
Other versions
EA032581B1 (ru
Inventor
Штефан Шунк
Мелани Райх
Флориан Якоб
Нильс Даманн
Михаэль Хауранд
Ахим Клесс
Марк Роджерс
Кэти Маккензи
Original Assignee
Грюненталь Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Грюненталь Гмбх filed Critical Грюненталь Гмбх
Publication of EA201692049A1 publication Critical patent/EA201692049A1/ru
Publication of EA032581B1 publication Critical patent/EA032581B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Изобретение относится к арилзамещенным гетероциклилсульфонам в качестве блокаторов потенциалзависимых кальциевых каналов, к фармацевтическим композициям, содержащим такие соединения, а также к таким соединениям для применения для лечения и/или профилактики боли и других заболеваний и/или расстройств.
EA201692049A 2014-04-14 2015-04-14 Гетероарилзамещенные гетероциклилсульфоны EA032581B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14001346 2014-04-14
PCT/EP2015/000782 WO2015158427A1 (en) 2014-04-14 2015-04-14 Heteroaryl substituted heterocyclyl sulfones

Publications (2)

Publication Number Publication Date
EA201692049A1 true EA201692049A1 (ru) 2017-04-28
EA032581B1 EA032581B1 (ru) 2019-06-28

Family

ID=50486704

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692049A EA032581B1 (ru) 2014-04-14 2015-04-14 Гетероарилзамещенные гетероциклилсульфоны

Country Status (16)

Country Link
US (2) US9879000B2 (ru)
EP (2) EP3131894A1 (ru)
JP (1) JP6673850B2 (ru)
KR (1) KR20160144487A (ru)
CN (1) CN106458956B (ru)
AR (1) AR100073A1 (ru)
AU (1) AU2015246387B2 (ru)
BR (1) BR112016023860A2 (ru)
CA (1) CA2945535A1 (ru)
CL (1) CL2016002615A1 (ru)
EA (1) EA032581B1 (ru)
IL (1) IL248250A0 (ru)
MX (1) MX2016013447A (ru)
PE (1) PE20161366A1 (ru)
TW (1) TW201620899A (ru)
WO (1) WO2015158427A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
EP3470406A1 (en) * 2014-04-14 2019-04-17 Grünenthal GmbH Aryl substituted heterocyclyl sulfones
TW201718557A (zh) * 2015-10-08 2017-06-01 歌林達有限公司 經吡唑基取代之四氫吡喃基碸
TW201726128A (zh) * 2015-10-08 2017-08-01 歌林達有限公司 經吡唑基取代之四氫哌喃基碸
JP6678779B2 (ja) 2016-06-13 2020-04-08 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒ（ｎｒ１ｈ４）調節化合物
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
AU2018243719B2 (en) 2017-03-28 2021-01-21 Gilead Sciences, Inc. Therapeutic combinations for treating liver diseases
EP3892278B1 (en) 2018-12-06 2024-02-28 Daiichi Sankyo Company, Limited Cycloalkane-1,3-diamine derivative
AU2020209564B2 (en) 2019-01-15 2022-12-01 Gilead Sciences, Inc. FXR (NR1H4) modulating compounds
CA3233305A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
IL298694A (en) * 2019-10-18 2023-02-01 Fmc Corp Method for preparing 5-bromo-2-(3-chloro-pyridin-2-yl)-2H-pyrallose-3-carboxylic acid
KR20220084092A (ko) * 2019-10-18 2022-06-21 에프엠씨 코포레이션 5-브로모-2-(3-클로로-피리딘-2-일)-2h-피라졸-3-카복실산의 제조 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1138680A1 (en) * 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
WO2007125398A2 (en) * 2006-04-27 2007-11-08 Pfizer Japan Inc. : sulfonamide compounds as antagonists of the n-type calcium channel
GB0813142D0 (en) * 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
EP2477963A4 (en) * 2009-09-18 2013-02-27 Zalicus Pharmaceuticals Ltd ARYLSULFON DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
EP3470406A1 (en) * 2014-04-14 2019-04-17 Grünenthal GmbH Aryl substituted heterocyclyl sulfones
TW201718557A (zh) 2015-10-08 2017-06-01 歌林達有限公司 經吡唑基取代之四氫吡喃基碸
TW201726128A (zh) 2015-10-08 2017-08-01 歌林達有限公司 經吡唑基取代之四氫哌喃基碸

Also Published As

Publication number Publication date
KR20160144487A (ko) 2016-12-16
CN106458956B (zh) 2019-06-14
CA2945535A1 (en) 2015-10-22
JP2017511352A (ja) 2017-04-20
CL2016002615A1 (es) 2017-04-28
US20150291572A1 (en) 2015-10-15
IL248250A0 (en) 2016-11-30
JP6673850B2 (ja) 2020-03-25
AR100073A1 (es) 2016-09-07
WO2015158427A1 (en) 2015-10-22
US20170121314A1 (en) 2017-05-04
AU2015246387A1 (en) 2016-12-01
MX2016013447A (es) 2017-01-18
EP3495360A1 (en) 2019-06-12
EA032581B1 (ru) 2019-06-28
US9926302B2 (en) 2018-03-27
AU2015246387B2 (en) 2018-11-22
EP3131894A1 (en) 2017-02-22
BR112016023860A2 (pt) 2017-08-15
TW201620899A (zh) 2016-06-16
US9879000B2 (en) 2018-01-30
CN106458956A (zh) 2017-02-22
PE20161366A1 (es) 2017-01-15

Similar Documents

Publication Publication Date Title
EA201692049A1 (ru) Гетероарилзамещенные гетероциклилсульфоны
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201890204A1 (ru) Антибактериальные соединения
EA201992878A1 (ru) Соединения для лечения болезни хантингтона
EA201592143A1 (ru) Новые бициклические ингибиторы бромодомена
EA201990043A1 (ru) Антибактериальные соединения
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201990240A1 (ru) Новые трициклические соединения в качестве противораковых средств
EA201591746A1 (ru) Способы и композиции для ингибирования бромодомен-содержащих белков
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201491505A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201691582A1 (ru) Новые фармацевтические препараты
EA201891251A1 (ru) Бициклические ингибиторы pad4
EA201491412A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201592024A1 (ru) Замещенные 5-(3,5-диметилизоксазол-4-ил)-индолин-2-оны
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
EA201691853A1 (ru) Агонисты мускариновых рецепторов
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201692007A1 (ru) Соединения изоиндолинона в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных с ними нарушений
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
EA201692008A1 (ru) Замещенные сконденсированные гетероциклы в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных нарушений
EA201790570A1 (ru) Модуляторы р2х7

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU